Save with our new Non-Invasive Prenatal Package! This great value package includes our Non-Invasive Prenatal Paternity DNA Test as well as our Prenatal Peace Genetic Screening AND our NEW Baby Gender Screening! All for one low price.
Our ‘Prenatal Peace’ or ‘NIFTY™’ (Non-Invasive Fetal Trisomy test) is a safe, simple, non-invasive prenatal testwhich offers screening for certain genetic conditions from as early as week 10 of pregnancy.Using the latest genetic sequencing technology, NIFTY™ has over >99% accuracy for the three most common trisomy conditions present at birth, which are Down Syndrome, Edwards Syndrome and Patau Syndrome.
Are you having a baby boy or baby girl? Are you curious to find out? With a 98% accuracy rate, our baby gender DNA test using a simple Maternal blood sample will give you the definite answer you need as early as 10 weeks of Pregnancy. The test we offer has been extensively validated and endorsed and no other baby gender test offers such accurate results so early in your pregnancy.

Postnatal Peace” or “Nova™” is a genetic screening test (Newborn – 5 years) that determines a baby’s risk for 50 inherited disorders, as well as providing personalised genetic information on the metabolism of 20 drugs. Nova™ utilises Next Generation sequencing technology, coupled with the leading genetics bioinformatics software. Postnatal peace is able to offer the most comprehensive and accurate newborn screening test that is over 99.99% accurate.

Our Inherited Disease Panel tests over 300 genes applicable to over 700 unique inherited diseases, including neuromuscular, cardiovascular, developmental, and metabolic diseases. This screening test can be used for preconception testing of prospective parents to screen for potential overlapping genetic disorders as well as diagnosis of inherited conditions.

Pharmacogenomics (PGx) is the analysis of how genes affect a person’s response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person’s genetic makeup. PGx can provide information about a patient’s genetic likelihood to respond to a given medication or risk of an adverse drug response (ADR).

Cystic fibrosis is a condition which mainly affects the lungs and pancreas, but can affect other parts of the body, including the liver, nose and sinuses, reproductive organs, and sweat glands. Our Cystic Fibrosis testing is performed using massive parallel sequencing (next generation sequencing) which allows for the analysis of exons, intron-exon boundaries, and UTRs that contain common mutations in the CFTR gene. This methodology with sequence analysis of all exons, intron/ exon borders, promoter regions, and specific intronic regions detects more than 98% of CFTR mutations.

This test screens for mutations in 17 genes that can cause early onset dementia. The results from this screening test can aid in diagnosis, provide additional information to an already diagnosed patient and identify potential risk genes causing dementia in the family.

An allergy is a response of the immune system where the body’s defense can react to a harmless substance such as pollen, food and even drugs. Almost anything can trigger an allergic reaction, which can range from mild and sometimes it can be life-threatening. We are pleased to now be offering New Clinical Diagnostic Solutions for Allergy and Autoimmune Testing.

This exciting panel tests for 24 carefully selected DNA regions that can predict both hair and eye colour. Our Phenotype panel is capable of simultaneously predicting both the eye and hair colour of a person from DNA via assessment of carefully selected DNA markers. Using a special prediction model, the test enables us to establish categorical eye colour as well as shades of hair colour.

Autism is a lifelong condition that belongs to a group of neurodevelopmental disabilities known as Autism Spectrum Disorders (ASDs). Our Autism screening Panel analyses over 230 genes associated with ASD and can aid in diagnosis of patients with suspected ASDs. For many children and adults, the everyday life can be significantly improved by a diagnosis and appropriate specialist support.

Establish your genetic risk of hereditary cancers. We offer a cancer panel test which will look for a total of 92 mutations associated with hereditary cancers. The genetic predisposition test for cancer is a powerful tool that can help you reduce your risks or undertake measures that will help you detect any cancers as early as possible.

Genetic Testing is now available for ctDNA in blood. DNA is extracted from plasma and highly sensitive testing is then used to detect specific DNA mutations in the circulating cell-free tumour DNA enabling early detection of cancer, monitoring of disease progression and response to treatment.

Targeted Sequencing Panel covering 50 genes involved in cancer. This panel is ideal for ovarian cancer, breast cancer, prostate cancer and bladder cancer, providing analysis of genes that may offer suitable drug targets.
Targeted Sequencing Panel covering 22 genes involved in lung cancer, bowel cancer, melanoma and pancreatic cancer. For lung cancer, we are also able to test for RNA fusions including ALK, RET, ROS-1 and NTRK-1.
Targeted Sequencing Panel covering 19 genes involved in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
Noonan syndrome is a condition that affects 1 in 1000-2500 individuals. Symptoms can include characteristic facial features, heart abnormalities, short stature and intellectual disability.
Folate deficient? This test screens for the two most common MTHFR gene mutations that can be involved in reduced folate metabolism and/or elevated blood homocysteine levels.
Several other molecular pathology tests are under development. For information about specific requirements please contact the laboratory. Medicare rebates may be available on some tests.